Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Drug Profile

Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Alternative Names: Fluenz Tetra; FluMist Quadrivalent; Influenza vaccine live-intranasal - MedImmune; MEDI-3250; MEDI-8662; Q-LAIV Flu Vac; Q-LAIV Flu Vaccination; Q/LAIV; Quadrivalent live attenuated influenza vaccine - MedImmune; Quadrivalent live attenuated seasonal influenza vaccine - MedImmune; VN-0107

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator MedImmune
  • Developer Japan Vaccine; MedImmune
  • Class Influenza virus vaccines-live
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 11 Oct 2016 Daiichi Sankyo plans a phase III trial for Influenza virus infections (In adolescents, In children, Prevention) in Japan (Intranasal) (JapicCTI163400)
  • 01 Jun 2016 Preregistration for Influenza virus infections (Prevention) in Japan (Intranasal) (Daiichi Sankyo pipeline, August 2016)
  • 02 Sep 2015 FluMist® quadrivalent licensed to Daiichi Sankyo in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top